Streptococcus Pneumoniae Serotype 23B Conjugate Vaccine
This is a pneumococcal conjugate vaccine that targets Streptococcus pneumoniae serotype 23b. The vaccine works by conjugating the bacterial capsular polysaccharide antigen to CRM197, a non-toxic diphtheria toxin protein carrier, which enhances the immune response compared to polysaccharide-only vaccines. This type of vaccine is designed to induce protective antibodies against pneumococcal infections caused by this specific serotype.
A pneumococcal conjugate vaccine using CRM197 protein carrier to induce immunity against S. pneumoniae serotype 23b infection.
Key facts at a glance
- RxNorm
- 2686922
- Generic
- Streptococcus Pneumoniae Serotype 23b Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease, pneumonia, and otitis media caused by Streptococcus pneumoniae serotype 23b. May be used in populations requiring protection against this specific pneumococcal serotype.
The capsular polysaccharide antigen of S. pneumoniae serotype 23b is chemically conjugated to CRM197 protein carrier. This conjugation converts a T-cell independent antigen into a T-cell dependent antigen, enhancing immunogenicity and enabling effective immune responses in populations like infants who typically respond poorly to polysaccharide antigens alone.
This vaccine targets a specific pneumococcal serotype and may be used as part of a comprehensive immunization strategy. Administration should follow established guidelines for pneumococcal vaccines. Patients with known hypersensitivity to vaccine components or to diphtheria toxoid derivatives should not receive this vaccine. Consult prescribing information for complete dosing and administration details.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 31, 2026. · Read our editorial policy